NCT01789255 · REGISTRY CONDITION SEARCH

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2018-07-24

This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies. Vorinostat, tacrolimus, and methotrexate may be an effective treatment for GVHD caused by a bone marrow transplant.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100

→

outcome · POSTED

Mean Percent of Planned Dose Administered

→

outcome · POSTED

The Percentage of Patients Alive Without GVHD or Use of Steroids

→

outcome · POSTED

The Percentage of Patients Alive at 1 Year

→

outcome · POSTED

The Percentage of Patients With Relapse at 1 Year

→

outcome · POSTED

Median Ac-H3 Levels in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat

→

outcome · POSTED

Median Plasma Concentration of IL-6 in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * A prospective patient for allogeneic HSCT for hematologic conditions, both malignant and non-malignant; donor can be unrelated marrow or peripheral blood cells; a patient with history of central nervous system (CNS) involvement is eligible if CNS disease is in remission at time of study consideration * The donor and recipient must have a human leukocyte antigen (HLA)-8/8 allelic match at the HLA-A, -B, -C, and -DRB1; high-resolution typing is required for all alleles * Diagnoses to be included: * Acute myelogenous leukemia at the following stages: * First remission * Second or subsequent remission * Complete remission is defined as the absence of blasts in the peripheral circulation at the time of enrollment and \< 5% blasts in the bone marrow * Chronic myelogenous leukemia at the following stages: * First or subsequent chronic phase: * Patient refused tyrosine kinase therapy or is otherwise not suited for it * Stable, not hematologic remission: blasts present in marrow and/or peripheral blood, but disease does not qualify as accelerated or blast phase * Hematologic remission: no blast cells or precursor cells in the blood or marrow * Partial cytogenetic remission: Philadelphia chromosome positive (Ph+) metaphases \> 0% but \< 35% * Complete cytogenetic remission: absence of Ph+ metaphases * Accelerated phase - any one of the following symptoms: * White blood cells (WBC) difficult to control (\> 50 x 10\^9/L despite therapy) * Rapid doubling of WBC (\< 5 days) * 10% blasts in blood or marrow * 20% blasts and/or promyelocytes in blood or marrow * 20% basophils and/or eosinophils in blood * Anemia or thrombocytopenia unresponsive to standard treatment * Persistent thrombocytosis (\> 1000 x 10\^9/L) * Cytogenetic abnormalities in addition to Ph+ * Increasing splenomegaly * Marrow fibrosis * Myelodysplastic syndromes at any of the following stages: * Refractory anemia * Refractory anemia with ringed sideroblasts * Refractory cytopenia with multilineage dysplasia * Refractory cytopenia with multilineage dysplasia and ringed sideroblasts * Refractory anemia with excess blasts-1 (5-10% blasts) * Refractory anemia with excess blasts-2 (10-20% blasts) * Myelodysplastic syndrome, unclassified * Myelodysplastic syndrome (MDS) associated with isolated del (5q) * Chronic myelomonocytic leukemia * Primary Myelofibrosis * Intermediate-2 risk or high risk disease * Patients should have extinguished standard of care options prior to being considered for this trial * Chronic lymphocytic leukemia * Complete remission: the disease is completely absent and no relapse occurred prior to the preparative regimen; requires all of the following: * Nodular partial remission: complete response with persistent lymphoid nodules in bone marrow * Partial remission: reduction of more than 50% in the disease burden regardless of the number of lines of therapy received * Mature B cell malignancies * Patients should have extinguished standard of care options prior to being considered eligible for this trial * First complete remission (CR1) confirmed: complete disappearance of all known disease; the term "confirmed" is defined as a laboratory and/or pathological or radiographic determination. * CR1 unconfirmed (CRU1): complete disappearance of all known disease with the exception of persistent scan abnormalities of unknown significance; the term "unconfirmed" is defined as scan abnormalities of unknown significance that are not biopsied or otherwise evaluated * Second or subsequent complete remission (CR2+) confirmed: the recipient relapsed, then achieved complete absence of disease without radiographic evidence of disease * CR2+ unconfirmed: the recipient has achieved a second or subsequent complete response but has persistent radiographic abnormalities of unknown significance. * Partial remission: reductions of \>= 50% in greatest diameter of all sites of known disease and no new sites * Karnofsky \>= 70% * Life expectancy of greater than 6 months * Total bilirubin =\< 2.5 mg% (unless from Gilbert's disease or disease-related) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) \< 3.0 X institutional upper limit of normal * Estimated or actual glomerular filtration rate (GFR) \> 50 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal; GFR should be corrected for body surface area (BSA) * Diffusing capacity of the lung for carbon monoxide (DLCO) \> 50%; DLCO should be corrected for hemoglobin * Forced expiratory volume in 1 second (FEV1) \> 50% * Forced vital capacity (FVC) \> 50% * Ejection fraction \>= 50% * The effects of vorinostat on the developing human fetus are unknown; for this reason and because histone deacetylase inhibitor agents as well as other therapeutic agents used in this trial (e.g., tacrolimus and methotrexate) are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of vorinostat administration * Ability to understand and the willingness to sign a written informed consent document * Patients must be able to swallow capsules/tablets Exclusion Criteria: * Patients who are not a candidate for an unrelated donor allogeneic HSCT based on the current institutional bone marrow transplant (BMT) program clinical practice guidelines; organ function criteria will be utilized per the current institutional BMT program clinical practice guidelines; there will be no restriction to study entry based on hematological parameters * History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat * Patients undergoing a total body irradiation (TBI)-based conditioning regimen (TBI 1200 centigray \[cGy\]) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; patients still under therapy for presumed or proven infection are eligible provided there is clear evidence (radiographic findings and/or culture results) that the infection is well-controlled; patients under treatment for infection will be enrolled only after clearance from the Principal Investigator (PI) * Pregnant women are excluded from this study because vorinostat is a histone deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat, breastfeeding should be discontinued if the mother is treated with vorinostat * Patients with evidence of human immunodeficiency virus (HIV) seropositivity and/or positive polymerase chain reaction (PCR) assay, human T-lymphotropic virus (HTLV)1/HTLV2 seropositivity; the safety of allogeneic HSCT is not yet well-established for this population * Patients with evidence of hepatitis B or hepatitis C PCR positivity; hepatitis reactivation following myelosuppressive therapy can lead to fatal complications * Patients with a history of prolonged corrected QT interval (QTc) syndrome * Patients asking or who have had prior treatment with a drug like vorinostat (i.e., valproic acid) within the last 30 days
healthy Volunteers: false
maximum Age: 75 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
intervention Names
Drug: vorinostat
Drug: tacrolimus
Drug: cyclosporine
Drug: methotrexate
Other: laboratory biomarker analysis
Other: pharmacological study
label
Supportive care (vorinostat, tacrolimus, methotrexate)
type
EXPERIMENTAL

interventions

arm Group Labels
Supportive care (vorinostat, tacrolimus, methotrexate)
description
Given PO
name
vorinostat
other Names
L-001079038
SAHA
suberoylanilide hydroxamic acid
Zolinza
type
DRUG
arm Group Labels
Supportive care (vorinostat, tacrolimus, methotrexate)
description
Given IV or PO
name
tacrolimus
other Names
FK 506
Prograf
type
DRUG
arm Group Labels
Supportive care (vorinostat, tacrolimus, methotrexate)
description
Given IV or PO
name
cyclosporine
other Names
ciclosporin
cyclosporin
cyclosporin A
CYSP
Sandimmune
type
DRUG
arm Group Labels
Supportive care (vorinostat, tacrolimus, methotrexate)
description
Given IV
name
methotrexate
other Names
amethopterin
Folex
methylaminopterin
Mexate
MTX
type
DRUG
arm Group Labels
Supportive care (vorinostat, tacrolimus, methotrexate)
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER
arm Group Labels
Supportive care (vorinostat, tacrolimus, methotrexate)
description
Correlative studies
name
pharmacological study
other Names
pharmacological studies
type
OTHER

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

SUPPORTIVE_CARE

Enrollment

count: 12
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The incidence of grade 2-4 acute GVHD (Graft Versus Host Disease) by day 100 Grade 2 GVHD: Maculopapular rash covering 25-50% of BSA (Body Surface Area), bilirubin between 3.1-6 mg/dl, and/ or adult stool output between 1000-1500 ml/day (child between 20-30 ml/kg/day). Grade 3 GVHD: Maculopapular rash covering \>50% of BSA, bilirubin between 6.1-15 mg/dl, and/ or adult stool output \>1500 ml/day (child \>30 ml/kg/day). Grade 4 GVHD: Generalized erythroderma plus bullous formation and desquamation \>5% BSA, bilirubin \>15 mg/dl, and/ or severe abdominal pain with or without ileus, or grossly bloody stool.
measure
The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100
time Frame
Day 100

secondary Outcomes

description
The addition of vorinostat to tacrolimus and methotrexate for GVHD prophylaxis will be considered feasible if 60% or more of the planned doses are administered.
measure
Mean Percent of Planned Dose Administered
time Frame
Up to day 30
description
The percentage of patients alive without GVHD or use of steroids at 1 year.
measure
The Percentage of Patients Alive Without GVHD or Use of Steroids
time Frame
Up to 1 year
description
The percentage of patients alive at 1 year
measure
The Percentage of Patients Alive at 1 Year
time Frame
Up to 1 year
measure
The Percentage of Patients With Relapse at 1 Year
time Frame
Up to 1 year
description
Median Ac-H3 levels ( depicted as a ratio of ac-H2 optical density (OD) and beta actin OD) were compared in patients treated with Vorinostat to patients not treated with Vorinostat. Optical Density is a dimensionless unit.
measure
Median Ac-H3 Levels in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat
time Frame
Up to day 100
description
Median plasma concentration of IL-6 (Interleukin-6 cytokine) was compared in patients treated with Vorinostat to those not treated with Vorinostat.
measure
Median Plasma Concentration of IL-6 in Patients Treated With Vorinostat and Patients Not Treated With Vorinostat
time Frame
Up to day 100

Full study description

brief Summary: This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies. Vorinostat, tacrolimus, and methotrexate may be an effective treatment for GVHD caused by a bone marrow transplant.
detailed Description: PRIMARY OBJECTIVES: I. To assess the safety and the feasibility of the addition of vorinostat to tacrolimus and methotrexate GVHD prophylaxis. SECONDARY OBJECTIVES: I. To determine day 100 grades 2-4 acute GVHD. II. To determine 1-year overall survival and relapse-free survival. III. To correlate plasma concentrations of inflammatory markers of acute GVHD. IV. To correlate protein acetylation in peripheral blood mononuclear cells before and after administration of vorinostat. OUTLINE: Patients receive vorinostat orally (PO) twice daily (BID) on days -10 to 100. Beginning on day -3, patients receive tacrolimus intravenously (IV) continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV once daily (QD) on days 1, 3, 6, and 11. After completion of study treatment, patients are followed up periodically for 1 year.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-14d62f3d960d402a2eb1
requested nct id
NCT01789255
primary nct id
NCT01789255
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Testicular+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
payload sha256
4c3184c8b0c7025a1cde1f3e08ce917d5a29879d7a9981f88e2a6f67cc2d39a3
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-14d62f3d960d402a2eb1
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01789255
occurrences
context exact
NCT01789255
end
11
exact text
NCT01789255
start
0
offset unit
unicode_code_points
query cond
Testicular Cancer
query disease state id
ds-testicular-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
source file sha256
9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
source json pointer
/studies/36/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d76d067e0e640bfbf5c9bca8ead4286343428d879348166de5c5b3a1c0908a50
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Testicular+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-3100f44ec505fd918e3e
requested nct id
NCT01789255
primary nct id
NCT01789255
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Primary+Central+Nervous+System+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
5133d5efc2041fb2554b035b378f2db0c15cad34dada88cd170d20b9c4e7432a
payload sha256
55aad54c12419e2553007a122e56de5e687769e6f9f0e32b422e7684d523c51c
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-3100f44ec505fd918e3e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01789255
occurrences
context exact
NCT01789255
end
11
exact text
NCT01789255
start
0
offset unit
unicode_code_points
query cond
Primary Central Nervous System Lymphoma
query disease state id
ds-primary-central-nervous-system-lymphoma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-primary-central-nervous-system-lymphoma-000.json
source file sha256
5133d5efc2041fb2554b035b378f2db0c15cad34dada88cd170d20b9c4e7432a
source json pointer
/studies/38/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d76d067e0e640bfbf5c9bca8ead4286343428d879348166de5c5b3a1c0908a50
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Primary+Central+Nervous+System+Lymphoma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8774f84a93c8588adfbc
requested nct id
NCT01789255
primary nct id
NCT01789255
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
payload sha256
081d635fbbf73f197e16a13652fd02987fcb74c9cb188532ae0d8bbd037e9724
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8774f84a93c8588adfbc
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01789255
occurrences
context exact
NCT01789255
end
11
exact text
NCT01789255
start
0
offset unit
unicode_code_points
query cond
Juvenile Myelomonocytic Leukemia
query disease state id
ds-juvenile-myelomonocytic-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
source json pointer
/studies/98/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d76d067e0e640bfbf5c9bca8ead4286343428d879348166de5c5b3a1c0908a50
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-ba2eb16403a274a8a060
requested nct id
NCT01789255
primary nct id
NCT01789255
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
dae67de2f3a205a1c4c35c6d4db8996c1d835061304595a26f5fc96fb4de7196
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-ba2eb16403a274a8a060
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01789255
occurrences
context exact
NCT01789255
end
11
exact text
NCT01789255
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/693/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d76d067e0e640bfbf5c9bca8ead4286343428d879348166de5c5b3a1c0908a50
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f12658c7ae7ae167ad48
requested nct id
NCT01789255
primary nct id
NCT01789255
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
payload sha256
60966cefb5ac3851ef0981a78f461f2fe9f597345912ecc56c657a252bfc9878
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f12658c7ae7ae167ad48
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01789255
occurrences
context exact
NCT01789255
end
11
exact text
NCT01789255
start
0
offset unit
unicode_code_points
query cond
Small Intestine Cancer
query disease state id
ds-small-intestine-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
source json pointer
/studies/76/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d76d067e0e640bfbf5c9bca8ead4286343428d879348166de5c5b3a1c0908a50
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-f55c4094c2e3e12809ec
requested nct id
NCT01789255
primary nct id
NCT01789255
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hairy+Cell+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
payload sha256
2da0845112a38a57e88bf386a7cb55581e49a6d8c7c9a6799af2ffb1288da54d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-f55c4094c2e3e12809ec
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01789255
occurrences
context exact
NCT01789255
end
11
exact text
NCT01789255
start
0
offset unit
unicode_code_points
query cond
Hairy Cell Leukemia
query disease state id
ds-hairy-cell-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hairy-cell-leukemia-000.json
source file sha256
8b9a346048372591e3ee0de631ceead25528dc1d384a69971d454af93b26921d
source json pointer
/studies/32/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d76d067e0e640bfbf5c9bca8ead4286343428d879348166de5c5b3a1c0908a50
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hairy+Cell+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice